This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, A. A.
Right arrow Articles by Triccas, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, A. A.
Right arrow Articles by Triccas, J. A.

 Previous Article  |  Next Article 

Infection and Immunity, January 2007, p. 523-526, Vol. 75, No. 1
0019-9567/07/$08.00+0     doi:10.1128/IAI.00897-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Secretion of Functional Monocyte Chemotactic Protein 3 by Recombinant Mycobacterium bovis BCG Attenuates Vaccine Virulence and Maintains Protective Efficacy against M. tuberculosis Infection{triangledown}

Anthony A. Ryan,1 Joanne M. Spratt,1 Warwick J. Britton,1,2 and James A. Triccas1,3*

Mycobacterial Research Group, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW 2042, Australia,1 Discipline of Medicine,2 Discipline of Infectious Diseases and Immunology, University of Sydney, Camperdown, NSW 2006, Australia3

Received 7 June 2006/ Returned for modification 23 July 2006/ Accepted 17 October 2006

A strain of Mycobacterium bovis BCG that secretes high levels of functional murine monocyte chemotactic protein 3 (BCGMCP-3) was developed. Mice vaccinated with BCGMCP-3 displayed increased lymphocyte migration in vivo and augmented antigen-specific T-cell responses compared to mice vaccinated with BCG alone. The level of protection afforded by BCGMCP-3 was equivalent to that with control BCG; however, immunodeficient mice infected with BCGMCP-3 survived significantly longer than mice infected with the control BCG strain. Therefore, BCGMCP-3 may be a safer alternative than conventional BCG for vaccination of immunocompromised individuals.

* Corresponding author. Mailing address: Discipline of Infectious Diseases and Immunology, University of Sydney, Camperdown, NSW 2006, Australia. Phone: (612) 9351 6182. Fax: (612) 9351 4731. E-mail: jamiet{at}infdis.usyd.edu.au.

{triangledown} Published ahead of print on 30 October 2006.

Editor: J. L. Flynn

Infection and Immunity, January 2007, p. 523-526, Vol. 75, No. 1
0019-9567/07/$08.00+0     doi:10.1128/IAI.00897-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ryan, A. A., Wozniak, T. M., Shklovskaya, E., O'Donnell, M. A., Fazekas de St. Groth, B., Britton, W. J., Triccas, J. A. (2007). Improved Protection against Disseminated Tuberculosis by Mycobacterium bovis Bacillus Calmette-Guerin Secreting Murine GM-CSF Is Associated with Expansion and Activation of APCs. J. Immunol. 179: 8418-8424 [Abstract] [Full Text]  
  • Triccas, J. A., Shklovskaya, E., Spratt, J., Ryan, A. A., Palendira, U., Fazekas de StGroth, B., Britton, W. J. (2007). Effects of DNA- and Mycobacterium bovis BCG-Based Delivery of the Flt3 Ligand on Protective Immunity to Mycobacterium tuberculosis. Infect. Immun. 75: 5368-5375 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»